{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T23:22:30Z","timestamp":1776381750846,"version":"3.51.2"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":58,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-12599-x","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T15:53:03Z","timestamp":1768924383000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Success rates of DR-TB patients and associated factors in Tanzania: a six-year cohort study"],"prefix":"10.1186","volume":"26","author":[{"given":"Dennis M.","family":"Lyakurwa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isack Augustino","family":"Lekule","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shabani Ramadhani","family":"Mziray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert Fidelis","family":"Balama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Galus","family":"Sililo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riziki Michael","family":"Kisonga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiguang","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuzhi","family":"Ai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"key":"12599_CR1","unstructured":"WHO Definitions and reporting framework. for tuberculosis \u2013 2013 revision (updated December 2014 and January 2020) [Z]. 2020."},{"key":"12599_CR2","unstructured":"Organization W H. WHO consolidated guidelines on drug-resistant tuberculosis treatment [M]. Geneva: World Health Organization, 2019: Licence: CC BY-NC-SA 3.0 IGO. [Z]."},{"issue":"1","key":"12599_CR3","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41572-024-00504-2","volume":"10","author":"K DHEDA","year":"2024","unstructured":"Dheda K, Mirzayev F, Cirillo D M, et al. Multidrug-resistant tuberculosis [J]. Nat Rev Dis Primers. 2024;10(1):22.","journal-title":"Nat Rev Dis Primers"},{"issue":"Suppl 1","key":"12599_CR4","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1016\/j.ijid.2022.03.026","volume":"124","author":"S TIBERI","year":"2022","unstructured":"Tiberi S, Utjesanovic N, Galvin J, et al. Drug resistant TB - latest developments in epidemiology, diagnostics and management [J]. Int J Infect Dis. 2022;124(Suppl 1):S20\u20135.","journal-title":"Int J Infect Dis"},{"key":"12599_CR5","unstructured":"Global tuberculosis report 2018 Geneva: World Health Organization. 2018. Licence: CC BY-NC-SA 3.0 IGO. [R]."},{"key":"12599_CR6","doi-asserted-by":"publisher","first-page":"107849","DOI":"10.1016\/j.ijid.2025.107849","volume":"155","author":"A MATTEELLI","year":"2025","unstructured":"Matteelli A, Lovatti S. Update on multidrug-resistant tuberculosis preventive therapy toward the global tuberculosis elimination [J]. Int J Infect Dis. 2025;155:107849.","journal-title":"Int J Infect Dis"},{"issue":"5","key":"12599_CR7","doi-asserted-by":"publisher","first-page":"e62034","DOI":"10.1371\/journal.pone.0062034","volume":"8","author":"ND MPAGAMA S G, HEYSELL S K, NDUSILO","year":"2013","unstructured":"Mpagama SG, Heysell SK, Ndusilo ND, et al. Diagnosis and interim treatment outcomes from the first cohort of multidrug-resistant tuberculosis patients in Tanzania [J]. PLoS ONE. 2013;8(5):e62034.","journal-title":"PLoS ONE"},{"key":"12599_CR8","doi-asserted-by":"crossref","unstructured":"Rachmat B, Handayani K, Prasodjo RS. Factors affecting the success of MDR-TB treatment in high burden countries 2011\u20132021: a literature review [J]. AIP Conference Proceedings, 2023, 2683(1).","DOI":"10.1063\/5.0124939"},{"issue":"6","key":"12599_CR9","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.cmi.2017.09.012","volume":"24","author":"A JAVAID","year":"2018","unstructured":"Javaid A, Ullah I, Masud H, et al. Predictors of poor treatment outcomes in multidrug-resistant tuberculosis patients: a retrospective cohort study [J]. Clin Microbiol Infect. 2018;24(6):612\u20137.","journal-title":"Clin Microbiol Infect"},{"issue":"41","key":"12599_CR10","first-page":"907","volume":"4","author":"S ZHANG","year":"2022","unstructured":"Zhang S, Qiu L, Wu D, et al. Predictors for treatment outcomes in patients with Multi-drug resistant Tuberculosis - China, 2018\u20132020 [J]. China CDC Wkly. 2022;4(41):907\u201311.","journal-title":"China CDC Wkly"},{"issue":"4","key":"12599_CR11","doi-asserted-by":"publisher","first-page":"291","DOI":"10.5588\/ijtld.22.0638","volume":"27","author":"M KINTU T M, MWANAHAMISI B S, MUWANGU","year":"2023","unstructured":"Kintu T M, Mwanahamisi BS, Muwanguzi M, et al. Unfavorable treatment outcomes among patients with drug-resistant TB in Uganda [J]. Int J Tuberc Lung Dis. 2023;27(4):291\u20137.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"12","key":"12599_CR12","doi-asserted-by":"publisher","first-page":"e0266436","DOI":"10.1371\/journal.pone.0266436","volume":"17","author":"J FOSTER","year":"2022","unstructured":"Foster J, Marais BJ Mendezd, et al. Predictors of unfavourable treatment outcome in patients diagnosed with drug-resistant tuberculosis in the Torres Strait \/ Papua new Guinea border region [J]. PLoS ONE. 2022;17(12):e0266436.","journal-title":"PLoS ONE"},{"key":"12599_CR13","doi-asserted-by":"crossref","unstructured":"Khan F U, Rehman A U, Khan F U et al. Assessment of factors associated with unfavorable outcomes among drug-resistant TB patients: a 6-Year retrospective study from Pakistan [J]. Int J Environ Res Public Health, 2022, 19(3).","DOI":"10.3390\/ijerph19031574"},{"issue":"5","key":"12599_CR14","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/tmi.13867","volume":"28","author":"L MLEOH","year":"2023","unstructured":"Mleoh L, Mziray SR Tsered, et al. Shorter regimens improved treatment outcomes of multidrug-resistant tuberculosis patients in Tanzania in 2018 cohort [J]. Trop Med Int Health. 2023;28(5):357\u201366.","journal-title":"Trop Med Int Health"},{"key":"12599_CR15","doi-asserted-by":"crossref","unstructured":"Mrema G, Hussein A, Magoge W et al. Predictors of mortality among multidrug-resistant tuberculosis patients after decentralization of services in Tanzania from 2017 to 2019: retrospective cohort study [J]. Bull Natl Res Centre, 2024, 48(1).","DOI":"10.1186\/s42269-024-01235-w"},{"issue":"1","key":"12599_CR16","doi-asserted-by":"publisher","first-page":"44","DOI":"10.62438\/tunismed.v102i1.4521","volume":"102","author":"F TRITAR","year":"2024","unstructured":"Tritar F, Ben Saad S, Ferchichi M, et al. Risk factors for treatment failure in multidrug resistant tuberculosis in tunisia: an analytic study [J]. Tunis Med. 2024;102(1):44\u20138.","journal-title":"Tunis Med"},{"issue":"6","key":"12599_CR17","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3390\/tropicalmed8060315","volume":"8","author":"J FAYE L M, HOSU M C, IRUEDO","year":"2023","unstructured":"Faye LM, Hosu MC, Iruedo J, et al. Treatment outcomes and associated factors among tuberculosis patients from selected rural Eastern cape hospitals: an ambidirectional study [J]. Trop Med Infect Disease. 2023;8(6):315.","journal-title":"Trop Med Infect Disease"},{"key":"12599_CR18","doi-asserted-by":"crossref","unstructured":"Van de Water B, Abuelezam N, Hotchkiss J et al. The effect of HIV and antiretroviral therapy on drug-resistant tuberculosis treatment outcomes in Eastern Cape, South Africa: a cohort study [J]. Viruses, 2023, 15(11).","DOI":"10.3390\/v15112242"},{"issue":"2","key":"12599_CR19","doi-asserted-by":"publisher","first-page":"e0262318","DOI":"10.1371\/journal.pone.0262318","volume":"17","author":"H WAKJIRA M K, SANDY P T, MAVHANDU-MU","year":"2022","unstructured":"Wakjira MK, Sandy PT, Mavhandu-Mudzusi A H. Treatment outcomes of patients with MDR-TB and its determinants at referral hospitals in Ethiopia [J]. PLoS ONE. 2022;17(2):e0262318.","journal-title":"PLoS ONE"},{"issue":"1","key":"12599_CR20","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1186\/s12889-023-16259-6","volume":"23","author":"D APPIAH M A, ARTHUR J A, GBORGBLORVO","year":"2023","unstructured":"Appiah MA, Arthur JA, Gborgblorvor D, et al. Barriers to tuberculosis treatment adherence in high-burden tuberculosis settings in Ashanti region, ghana: a qualitative study from patient\u2019s perspective [J]. BMC Public Health. 2023;23(1):1317.","journal-title":"BMC Public Health"},{"issue":"1","key":"12599_CR21","doi-asserted-by":"publisher","first-page":"238","DOI":"10.4314\/ahs.v21i1.31","volume":"21","author":"R BATTE C, NAMUSOBYA M S, KIRABO","year":"2021","unstructured":"Batte C, Namusobya M S, Kirabo R, et al. Prevalence and factors associated with non-adherence to multi-drug resistant tuberculosis (MDR-TB) treatment at Mulago National referral Hospital, Kampala, Uganda [J]. Afr Health Sci. 2021;21(1):238\u201347.","journal-title":"Afr Health Sci"},{"key":"12599_CR22","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.2147\/PPA.S316253","volume":"15","author":"H LI","year":"2021","unstructured":"Li H, Zhang H, Xiong J, et al. Factors associated with medical Follow-Up adherence for patients on All-Oral regimen for Multidrug-Resistant tuberculosis in Shenzhen, China [J]. Patient Prefer Adherence. 2021;15:1491\u20136.","journal-title":"Patient Prefer Adherence"},{"key":"12599_CR23","doi-asserted-by":"publisher","first-page":"999","DOI":"10.2147\/IDR.S293583","volume":"14","author":"W XING","year":"2021","unstructured":"Xing W, Zhang R, Jiang W, et al. Adherence to multidrug resistant tuberculosis treatment and case management in Chongqing, China - A mixed method research study [J]. Infect Drug Resist. 2021;14:999\u20131012.","journal-title":"Infect Drug Resist"},{"issue":"9","key":"12599_CR24","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1093\/trstmh\/traa188","volume":"115","author":"JO BAKARE A M, UDUNZE O C, BAMIDELE","year":"2021","unstructured":"Bakare AM, Udunze OC, Bamidele JO, et al. Outcome of community-initiated treatment of drug-resistant tuberculosis patients in Lagos, Nigeria [J]. Trans R Soc Trop Med Hyg. 2021;115(9):1061\u20135.","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"2","key":"12599_CR25","first-page":"212","volume":"79","author":"P OCTAVIANI","year":"2024","unstructured":"Octaviani P, Ikawati Z, Yasin N M, et al. Interventions to improve adherence to medication on Multidrug-Resistant tuberculosis patients: A scoping review [J]. Med J Malaysia. 2024;79(2):212\u201321.","journal-title":"Med J Malaysia"},{"key":"12599_CR26","doi-asserted-by":"crossref","unstructured":"Law S, Daftary A, O\u2019Donnell M et al. Interventions to improve retention-in-care and treatment adherence among patients with drug-resistant tuberculosis: a systematic review [J]. Eur Respir J. 2019;53(1).","DOI":"10.1183\/13993003.01030-2018"},{"issue":"1","key":"12599_CR27","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1186\/s12879-021-06428-6","volume":"21","author":"TILAHUNB GASHU K D, GELAYE K A","year":"2021","unstructured":"Gashu KD, Gelaye KA TILAHUNB. Adherence to TB treatment remains low during continuation phase among adult patients in Northwest Ethiopia [J]. BMC Infect Dis. 2021;21(1):725.","journal-title":"BMC Infect Dis"},{"issue":"9","key":"12599_CR28","doi-asserted-by":"publisher","first-page":"e0255357","DOI":"10.1371\/journal.pone.0255357","volume":"16","author":"NGOC N B","year":"2021","unstructured":"Ngoc N B, Vu Dinh H, Thuy NT, et al. Active surveillance for adverse events in patients on longer treatment regimens for multidrug-resistant tuberculosis in Viet Nam [J]. PLoS ONE. 2021;16(9):e0255357.","journal-title":"PLoS ONE"},{"issue":"4","key":"12599_CR29","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S2213-2600(20)30047-3","volume":"8","author":"Z LAN","year":"2020","unstructured":"Lan Z, Ahmad N, Baghaei P, et al. Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis [J]. Lancet Respir Med. 2020;8(4):383\u201394.","journal-title":"Lancet Respir Med"},{"key":"12599_CR30","doi-asserted-by":"publisher","first-page":"790718","DOI":"10.3389\/fmed.2021.790718","volume":"8","author":"M ATIF","year":"2021","unstructured":"Atif M, Ahmed W, Nouman Iqbal M, et al. Frequency and factors associated with adverse events among Multi-Drug resistant tuberculosis patients in pakistan: A retrospective study [J]. Front Med (Lausanne). 2021;8:790718.","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"12599_CR31","doi-asserted-by":"publisher","first-page":"2332878","DOI":"10.1080\/20523211.2024.2332878","volume":"17","author":"S RAFIQUE","year":"2024","unstructured":"Rafique S, Ahmad N. Frequency, management and impact of adverse events on treatment outcomes in patients with multidrug resistant tuberculosis in Balochistan, Pakistan [J]. J Pharm Policy Pract. 2024;17(1):2332878.","journal-title":"J Pharm Policy Pract"},{"key":"12599_CR32","doi-asserted-by":"publisher","first-page":"876955","DOI":"10.3389\/fphar.2022.876955","volume":"13","author":"KHANA KHAN F U","year":"2022","unstructured":"Khan F U Khana, Khan F U, et al. Assessment of adverse drug Events, their risk Factors, and management among patients treated for Multidrug-Resistant TB: A prospective cohort study from Pakistan [J]. Front Pharmacol. 2022;13:876955.","journal-title":"Front Pharmacol"},{"issue":"1","key":"12599_CR33","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s12879-023-08085-3","volume":"23","author":"M ATEGYEKA P M, MUHOOZI","year":"2023","unstructured":"Ategyeka PM, Muhoozi M, Naturinda R, et al. Prevalence and factors associated with reported adverse-events among patients on multi-drug-resistant tuberculosis treatment in two referral hospitals in Uganda [J]. BMC Infect Dis. 2023;23(1):149.","journal-title":"BMC Infect Dis"},{"key":"12599_CR34","doi-asserted-by":"crossref","unstructured":"Hazra D, Lam C, Chawla K et al. Impact of whole-genome sequencing of mycobacterium tuberculosis on treatment outcomes for MDR-TB\/XDR-TB: a systematic review [J]. Pharmaceutics. 2023;15(12).","DOI":"10.3390\/pharmaceutics15122782"},{"issue":"11","key":"12599_CR35","doi-asserted-by":"publisher","first-page":"e0218299","DOI":"10.1371\/journal.pone.0218299","volume":"14","author":"M BHERING","year":"2019","unstructured":"Bhering M, Duarte R, Kritski A. Predictive factors for unfavourable treatment in MDR-TB and XDR-TB patients in Rio de Janeiro State, Brazil, 2000\u20132016 [J]. PLoS ONE. 2019;14(11):e0218299.","journal-title":"PLoS ONE"},{"issue":"4","key":"12599_CR36","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1093\/cid\/civ910","volume":"62","author":"JP CEGIELSKI","year":"2016","unstructured":"Cegielski JP, Van Der Walt Kurbatovae. Multidrug-Resistant tuberculosis treatment outcomes in relation to treatment and initial versus acquired Second-Line drug resistance [J]. Clin Infect Dis. 2016;62(4):418\u201330.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"12599_CR37","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/ddr.21498","volume":"80","author":"Y LI","year":"2019","unstructured":"Li Y, Sun F. Bedaquiline and Delamanid in the treatment of multidrug-resistant tuberculosis: promising but challenging [J]. Drug Dev Res. 2019;80(1):98\u2013105.","journal-title":"Drug Dev Res"},{"issue":"3","key":"12599_CR38","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1177\/0049475519833554","volume":"49","author":"D LYAKURWA","year":"2019","unstructured":"Lyakurwa D, Lyimo J. Successful treatment of XDR-TB patient in tanzania: report of the first XDR-TB patient [J]. Trop Doct. 2019;49(3):224\u20136.","journal-title":"Trop Doct"},{"issue":"1","key":"12599_CR39","doi-asserted-by":"publisher","first-page":"30","DOI":"10.37201\/req\/029.2022","volume":"36","author":"SS SHIROMWAR","year":"2023","unstructured":"Shiromwar SS, Khan A H Chidrawarv. A systematic review on extensively drug-resistant tuberculosis from 2009 to 2020: special emphases on treatment outcomes [J]. Rev Esp Quimioter. 2023;36(1):30\u201344.","journal-title":"Rev Esp Quimioter"},{"issue":"1","key":"12599_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4103\/ijmy.ijmy_217_22","volume":"12","author":"Y PUTRA O N, YULISTIANI","year":"2023","unstructured":"Putra ON, Yulistiani Y, Soedarsono S, et al. Favorable outcome of individual regimens containing bedaquiline and Delamanid in drug-resistant tuberculosis: A systematic review [J]. Int J Mycobacteriol. 2023;12(1):1\u20139.","journal-title":"Int J Mycobacteriol"},{"key":"12599_CR41","volume-title":"Programmatic management of drug-resistance tuberculosis","author":"Guidelines for the","year":"2011","unstructured":"Guidelines for the. Programmatic management of drug-resistance tuberculosis. Geneva: World Health Organization [Z]; 2011."},{"issue":"3","key":"12599_CR42","doi-asserted-by":"publisher","first-page":"1602308","DOI":"10.1183\/13993003.02308-2016","volume":"49","author":"D FALZON","year":"2017","unstructured":"Falzon D, Sch\u00fcnemann HJ Harausze, et al. World health organization treatment guidelines for drug-resistant tuberculosis, 2016 update [J]. Eur Respir J. 2017;49(3):1602308.","journal-title":"Eur Respir J"},{"key":"12599_CR43","unstructured":"Guidelines for Management of Multi-Drug Resistant \u2013 TB in Tanzania Second Edition. 2018: National Tuberculosis and Leprosy Program, Ministry of Health, Community Development, Gender Elderly and Children [Z]. 2018."},{"key":"12599_CR44","unstructured":"Guidelines for. Management of Drug Resistant \u2013 TB in Tanzania: Ministry of Health, Dodoma, Tanzania. National TB and Leprosy program. Third Edition [Z]. 2023."},{"key":"12599_CR45","unstructured":"NTLP. Manual for the management of tuberculosis and leprosy. 2013 [Z]\/\/PROGRAM N T A L. Ministry of Health and Social Welfare.The United Republic of Tanzania. 2013."},{"key":"12599_CR46","volume-title":"Guidelines for the programmatic management of drug-resistance tuberculosis [R]","author":"WHO","year":"2011","unstructured":"WHO. Guidelines for the programmatic management of drug-resistance tuberculosis [R]. Geneva: World Health Organization; 2011."},{"key":"12599_CR47","unstructured":"WHO. The shorter MDR-TB regimen features and composition 4\u20136 km-Mfx-Pto-Cfz-Z-H high-dose-E\/5 Mfx-Cfz-Z-E [Z]. 2016."},{"key":"12599_CR48","unstructured":"NTLP. Guidelines for Management of Drug Resistant \u2013 TB in Tanzania Ministry of Heath Third Edition, [Z]\/\/SERVICES D O P. Dodoma; Ministry of Health, Tanzania. 2023."},{"key":"12599_CR49","volume-title":"Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update","author":"WHO consolidated guidelines on tuberculosis","year":"2022","unstructured":"WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update. Geneva: World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO. [Z]."},{"issue":"2","key":"12599_CR50","first-page":"140","volume":"81","author":"LC MOSLEY W H, CHEN","year":"2003","unstructured":"Mosley WH, Chen LC. An analytical framework for the study of child survival in developing countries. 1984 [J]. Bull World Health Organ. 2003;81(2):140\u20135.","journal-title":"Bull World Health Organ"},{"issue":"1","key":"12599_CR51","doi-asserted-by":"publisher","first-page":"14144","DOI":"10.1038\/s41598-025-97027-x","volume":"15","author":"G BARTEKA","year":"2025","unstructured":"Barteka G, Bwayo D, Matovu JKB, et al. Treatment outcomes and predictors of success for multidrug resistant tuberculosis MDR TB in Ugandan regional referral hospitals [J]. Sci Rep. 2025;15(1):14144.","journal-title":"Sci Rep"},{"issue":"2","key":"12599_CR52","doi-asserted-by":"publisher","first-page":"e20210384","DOI":"10.36416\/1806-3756\/e20210384","volume":"48","author":"H HATAMI","year":"2022","unstructured":"Hatami H, Sotgiu G, Bostanghadiri N, et al. Bedaquiline-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis [J]. J Bras Pneumol. 2022;48(2):e20210384.","journal-title":"J Bras Pneumol"},{"key":"12599_CR53","doi-asserted-by":"crossref","unstructured":"Khan P Y, Franke M F, Hewison C et al. All-oral longer regimens are effective for the management of multidrug-resistant tuberculosis in high-burden settings [J]. Eur Respir J, 2022, 59(1).","DOI":"10.1183\/13993003.04345-2020"},{"issue":"10","key":"12599_CR54","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/S1473-3099(24)00228-7","volume":"24","author":"O KOROTYCH","year":"2024","unstructured":"Korotych O, Achar J. Effectiveness and safety of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis: a prospective cohort study [J]. Lancet Infect Dis. 2024;24(10):1151\u201361.","journal-title":"Lancet Infect Dis"},{"key":"12599_CR55","doi-asserted-by":"crossref","unstructured":"Alene KA, Wangdi K, Clements ACA. Impact of the COVID-19 pandemic on tuberculosis control: an overview [J]. Trop Med Infect Dis, 2020, 5(3).","DOI":"10.3390\/tropicalmed5030123"},{"issue":"3","key":"12599_CR56","doi-asserted-by":"publisher","first-page":"1901467","DOI":"10.1183\/13993003.01467-2019","volume":"55","author":"S ABIDI","year":"2020","unstructured":"Abidi S, Achar J, Assao Neino M, M, et al. Standardised shorter regimens versus individualised longer regimens for rifampin- or multidrug-resistant tuberculosis [J]. Eur Respir J. 2020;55(3):1901467.","journal-title":"Eur Respir J"},{"issue":"1","key":"12599_CR57","doi-asserted-by":"publisher","first-page":"2344821","DOI":"10.1080\/07853890.2024.2344821","volume":"56","author":"P GU","year":"2024","unstructured":"Gu P, Lu P, Ding H, et al. Effectiveness, cost, and safety of four regimens recommended by WHO for RR\/MDR-TB treatment: a cohort study in Eastern China [J]. Ann Med. 2024;56(1):2344821.","journal-title":"Ann Med"},{"issue":"13","key":"12599_CR58","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa1811867","volume":"380","author":"NUNN A J","year":"2019","unstructured":"Nunn AJ, Phillips PPJ, Meredith SK, et al. A trial of a shorter regimen for rifampin-resistant tuberculosis [J]. N Engl J Med. 2019;380(13):1201\u201313.","journal-title":"N Engl J Med"},{"issue":"4","key":"12599_CR59","doi-asserted-by":"publisher","first-page":"e543","DOI":"10.1016\/S2214-109X(22)00004-3","volume":"10","author":"F KAMARA R F, SAUNDERS M J, SAHR","year":"2022","unstructured":"Kamara RF, Saunders MJ, SAHR F, et al. Social and health factors associated with adverse treatment outcomes among people with multidrug-resistant tuberculosis in Sierra leone: a national, retrospective cohort study [J]. Lancet Global Health. 2022;10(4):e543\u201354.","journal-title":"Lancet Global Health"},{"issue":"8","key":"12599_CR60","doi-asserted-by":"publisher","first-page":"e0237355","DOI":"10.1371\/journal.pone.0237355","volume":"15","author":"HASSANE-HAROUNA S","year":"2020","unstructured":"Hassane-Harouna S, CHERIF G F, ORTUNO-GUTIERREZ N, et al. Better programmatic outcome with the shorter regimen for the treatment of multidrug-resistant tuberculosis (MDR-TB) in guinea: A retrospective cohort study [J]. PLoS ONE. 2020;15(8):e0237355.","journal-title":"PLoS ONE"},{"key":"12599_CR61","doi-asserted-by":"publisher","first-page":"973713","DOI":"10.3389\/fphar.2022.973713","volume":"13","author":"A WAHID","year":"2022","unstructured":"Wahid A, Ghafoor A, Khan AW, et al. Comparative effectiveness of individualized longer and standardized shorter regimens in the treatment of multidrug resistant tuberculosis in a high burden country [J]. Front Pharmacol. 2022;13:973713.","journal-title":"Front Pharmacol"},{"issue":"1","key":"12599_CR62","doi-asserted-by":"publisher","first-page":"47","DOI":"10.4269\/ajtmh.20-1361","volume":"105","author":"P HABIMANA D S, NGABONZIZA J C S, MIG","year":"2021","unstructured":"Habimana D S, Ngabonziza J C S, Migambi P, et al. Predictors of Rifampicin-Resistant tuberculosis mortality among HIV-Coinfected patients in Rwanda [J]. Am J Trop Med Hyg. 2021;105(1):47\u201353.","journal-title":"Am J Trop Med Hyg"},{"issue":"1","key":"12599_CR63","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ijtb.2023.05.005","volume":"71","author":"SH AHMED","year":"2024","unstructured":"Ahmed SH, Haider H, Moeed A, et al. Efficacy and safety of bedaquiline and Delamanid in the treatment of drug-resistant tuberculosis in adults: A systematic review and meta-analysis [J]. Indian J Tuberculosis. 2024;71(1):79\u201388.","journal-title":"Indian J Tuberculosis"},{"issue":"1","key":"12599_CR64","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1186\/s12879-021-06666-8","volume":"21","author":"J-Q WANG M-G, WU S-Q, HE","year":"2021","unstructured":"Wang M-G, Wu S-Q, He J-Q. Efficacy of bedaquiline in the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis [J]. BMC Infect Dis. 2021;21(1):970.","journal-title":"BMC Infect Dis"},{"issue":"7","key":"12599_CR65","doi-asserted-by":"publisher","first-page":"e062857","DOI":"10.1136\/bmjopen-2022-062857","volume":"12","author":"V PANFORD","year":"2022","unstructured":"Panford V, Kokuro Kumahe. Treatment outcomes and associated factors among patients with multidrug-resistant tuberculosis in Ashanti Region, ghana: a retrospective, cross-sectional study [J]. BMJ Open. 2022;12(7):e062857.","journal-title":"BMJ Open"},{"issue":"1","key":"12599_CR66","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1186\/s12879-021-06801-5","volume":"21","author":"JB BALUKU","year":"2021","unstructured":"Baluku JB, Mukasa D, Bongomin F, et al. Gender differences among patients with drug resistant tuberculosis and HIV co-infection in uganda: a countrywide retrospective cohort study [J]. BMC Infect Dis. 2021;21(1):1093.","journal-title":"BMC Infect Dis"},{"issue":"11","key":"12599_CR67","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.jfma.2015.10.002","volume":"115","author":"MA GADALLAH","year":"2016","unstructured":"Gadallah MA, Mokhtar A, RADY M, et al. Prognostic factors of treatment among patients with multidrug-resistant tuberculosis in Egypt [J]. J Formos Med Assoc. 2016;115(11):997\u20131003.","journal-title":"J Formos Med Assoc"},{"issue":"3","key":"12599_CR68","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.pulmoe.2018.03.004","volume":"24","author":"R MAR\u00c7\u00d4A","year":"2018","unstructured":"MAR\u00c7\u00d4A R, RIBEIRO A I, Z\u00c3O I, et al. Tuberculosis and gender - Factors influencing the risk of tuberculosis among men and women by age group [J]. Pulmonology. 2018;24(3):199\u2013202.","journal-title":"Pulmonology"},{"key":"12599_CR69","doi-asserted-by":"crossref","unstructured":"Mcquaid CF, Horton KC, Dean AS et al. The risk of multidrug- or rifampicin-resistance in males versus females with tuberculosis [J]. Eur Respir J, 2020, 56(3).","DOI":"10.1183\/13993003.00626-2020"},{"issue":"3","key":"12599_CR70","doi-asserted-by":"publisher","first-page":"107","DOI":"10.5588\/pha.23.0021","volume":"13","author":"DIERA MENDOZA-HISEY E C","year":"2023","unstructured":"Mendoza-Hisey EC Diera, Marquez N V, et al. Gender-related factors affecting access to TB services and treatment outcomes in the Philippines [J]. Public Health Action. 2023;13(3):107\u201311.","journal-title":"Public Health Action"},{"key":"12599_CR71","doi-asserted-by":"crossref","unstructured":"Quan D H, Kwong A J, HANSBRO P M et al. No smoke without fire: the impact of cigarette smoking on the immune control of tuberculosis [J]. Eur Respir Rev, 2022, 31(164).","DOI":"10.1183\/16000617.0252-2021"},{"issue":"1","key":"12599_CR72","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1186\/s12890-024-03350-w","volume":"24","author":"H KEBEDE A H, MAMO","year":"2024","unstructured":"Kebede AH, Mamo H. Multidrug-resistant tuberculosis treatment outcomes and associated factors at Yirgalem general Hospital, Sidama Region, South ethiopia: a retrospective cohort study [J]. BMC Pulm Med. 2024;24(1):527.","journal-title":"BMC Pulm Med"},{"issue":"5","key":"12599_CR73","doi-asserted-by":"publisher","first-page":"e26615","DOI":"10.1016\/j.heliyon.2024.e26615","volume":"10","author":"M KAZEMIAN S V, SHAKERI","year":"2024","unstructured":"Kazemian SV, Shakeri M. Prevalence, treatment outcomes and determinants of TB\/HIV coinfection: A 4-year retrospective review of National tuberculosis registry in a country in a MENA region [J]. Heliyon. 2024;10(5):e26615.","journal-title":"Heliyon"},{"issue":"4","key":"12599_CR74","doi-asserted-by":"publisher","first-page":"17","DOI":"10.21315\/mjms2016.23.4.3","volume":"23","author":"H ELMI O S, HASAN","year":"2016","unstructured":"Elmi O S, Hasan H, ABDULLAH S, et al. Treatment outcomes of patients with Multidrug-Resistant tuberculosis (MDR- TB) compared with Non-MDR-TB infections in Peninsular Malaysia [J]. Malays J Med Sci. 2016;23(4):17\u201325.","journal-title":"Malays J Med Sci"},{"key":"12599_CR75","doi-asserted-by":"publisher","first-page":"e62034","DOI":"10.1371\/journal.pone.0062034","volume":"8","author":"S MPAGAMA","year":"2013","unstructured":"Mpagama S, Heysell S, Ndusilo N, et al. Diagnosis and interim treatment outcomes from the first cohort of Multidrug-Resistant tuberculosis patients in Tanzania [J]. PLoS ONE. 2013;8:e62034.","journal-title":"PLoS ONE"},{"key":"12599_CR76","doi-asserted-by":"crossref","unstructured":"Tr\u00e9bucq A, Decroo T, Van Deun A et al. Short-course regimen for multidrug-resistant tuberculosis: a decade of evidence [J]. J Clin Med.2019;9(1).","DOI":"10.3390\/jcm9010055"},{"key":"12599_CR77","doi-asserted-by":"crossref","unstructured":"Mziray S R Mleohl. Tsere D, et al. Shorter regimens improved treatment outcomes of multidrug-resistant tuberculosis patients in Tanzania in 2018 cohort [J]. Volume 28. Tropical Medicine & International Health. 2023;357\u201366. 5.","DOI":"10.1111\/tmi.13867"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-12599-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-12599-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-12599-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T08:03:15Z","timestamp":1773907395000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-12599-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":77,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["12599"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-12599-x","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]},"assertion":[{"value":"3 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The ethics committee\/IRB of Southern Medical University and the Tanzanian Ministry of Health approved the study protocol for this study. This study was performed in line with the principles of the Declaration of Helsinki. We used anonymized and de-identified data to protect the privacy and confidentiality of individuals represented in the data set, rendering informed consent not necessary. The study adhered to National Institute of Medical Research (NIMR) and data protection. Access to data was restricted to authorized personnel involved in the research. The approve to publish this data was obtained from Tanzania Ministry of Health.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Approved by Tanzania Ministry of Health.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"586"}}